Q-omics provides the consensus-scored P4HA3 profile across patient tissues and cancer cell-line models. P4HA3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, P4HA3 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, P4HA3 RNA expression shows 20,440 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRP, HNSC, and BRCA as cancer lineages where P4HA3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for P4HA3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes P4HA3 survival associations across molecular data types. P4HA3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible P4HA3 RNA expression–survival associations across cancer types. High P4HA3 expression shows unfavorable associations in KIRP, BLCA, CESC, LUSC, UVM and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for P4HA3 RNA expression.
This table summarizes P4HA3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for P4HA3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. P4HA3 shows higher tumor expression in HNSC, KIRC, COAD, LUAD, STAD and BRCA. The HNSC box plot shows higher P4HA3 RNA expression in tumor versus normal tissue (log2 FC = +1.797, t-test p < 0.001).
This table shows molecular features associated with P4HA3 in patient tissues and cancer cell lines. In patient samples, P4HA3 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, P4HA3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
